Approximately 22% of cytogenetically normal acute myeloid leukemia (CN-AML) patients carry a DNMT3A mutation, from which about 60% are localized in the catalytic domain, at the R882 hotspot [22, 27]. Here, DNMT3A is linked to acute myeloid leukemia.